DRUG DISCOVERY AND DEVELOPMENT 5


and reports, marketing authorisation and change procedures and post- marketing surveillance.


Tese new commitments, which have been extended indefinitely, are based on the achievements of the previous arrangements between the EMA, the European Commission and the FDA. A report of the current status of agreement was issued in Oct. 2009, the ‘Medicines Regulation: Transatlantic Administrative Simplification Action Plan Implementation Report’.


Te main objective, as the title suggests, is to better utilise agency resources to “maintain or increase current levels of public health protection”. Te report identifies areas of cooperation such as biomarker development and joint qualification, combating counterfeit medicines, collaboration on development of medicinal products for children, convergence of risk management formats and others.


Streamlined process In Febuary 2010, the FDA and EMA agreed to accept a single orphan drug designation annual report. Te streamlined process is designed “to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the US and the EU. “


In April 2009, the EC, EMA and Health Canada signed an Implementation Plan for Regulatory Cooperation on Medicinal.


Tis plan puts into affect a sharing of arrangement of such things as listings of GCP and GMP inspections outside of respective territories, database information, guideline and guidance documents, and passing of information through periodic meetings between the parties.


Te plan also calls for ad-hoc exchanges with specific timeframes to respond depending on the category of need - urgent, expedited or standard. Initially, ad-hoc areas will focus on evaluation of applications for marketing authorisation, post-authorisation pharmacovigilance data, advance notice of regulatory sanctions before release of information to public domain, cooperation respecting the development of guidance documents, among others.


Europe and China In 2007, the European Commission signed a ‘consultation and cooperation mechanism’ between the Directorate-General for Enterprise and Industry and the Chinese State Food and Drug Authority (SFDA).


Te agreement is designed to help with the implementation of similar good manufacturing practice (GMP) and good clinical practice (GCP) standards to those applied in the European Union, to facilitate the use of products and data coming from China and helping to ensure a global approach to the manufacture and supervision of medicinal products in the long term.


In 2010, the European Commission and the SFDA agreed to a specific action plan on GMP and GCP inspections.


International organisational reforms In August 2010, the WHO published proposed additions and changes for sections of the WHO GMP Main Principles for Pharmaceutical Products.


Te draft proposes language is in line with how other major regulatory agencies have updated their documents.


Te draft introduces the idea of a system for quality risk management as a systematic way of assessing, controlling, communicating and reviewing risks to the quality of a medicinal product. It offers suggested wording for areas of overall


quality assurance, and specifically product quality review, supplier’s audits, personnel over quality units of QA and QC functions, packaging operations, batch record review and more.


In June 2010, the European Commission hosted a meeting with regulatory bodies to discuss enhanced international cooperation in the field of APIs.


Te response, according to PIC/S, is that “the PIC/S Expert Circle on APIs has started developing, in co-operation with other partners (for example, EDQM, EMA, ICH, US FDA, WHO, etc), an international training for inspectors on APIs. Te training will focus on i) an introduction to ICH Q7 (basic course) and ii) on how to inspect APIs (advanced course)”. Tis is another example of attempts to harmonise the interpretation of regulations with inspections conducted across the globe.


Implications for industry It was not long ago when regulations were created in isolation by regulators within each respective country. Problems were addressed with more regulation on top of existing laws.


Many factors have combined to boost governments’ desires to collaborate on pharmaceutical regulatory issues: explosive new technologies such as gene sequencing and diagnostic imaging; an aging population in parts of the world and underserved populations on other parts; pandemics and similar health crises requiring industry to mobilise rapidly to develop and produce medicines; among other factors.


Te tipping point for harmonisation has arrived. Not only are regulators establishing agreements to share information among agencies but also to be more transparent about how they operate.


Tis is good news for industry. Te days of different interpretations of the same rule are fading away thanks


to the work of Te Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (jointly referred to as PIC/S). Currently 37 participating authorities recognise the PIC/S GMP for guidance to assure high standards of quality in the development, manufacture and control of medicinal products.


Te organisation trains inspectors from member agencies to develop consistency of handling audits. Te PIC/S and EU GMPs virtually mirror each other in terms of GMP requirements, positioning the group as a central resource for regulatory and industry guidance.


In Octber 2010, the meeting of the WHO Expert Committee on Specification for Pharmaceutical Preparations will underscore this point with its draft advice on risk assessment.


Te text draws from guidelines of regulatory bodies in this area, aligning its thinking with them.


As the union of co-operation among independent agencies progresses so too will the spread of harmonised quality standards be adopted by any country wishing to export its medicines and raw materials. In the ever shifting economies where development, trials and manufacturing can easily move about the globe, harmonisation will ultimately encompass every geographic location.


Regulatory compliance Globalisation of regulatory standards is thankfully matched by growth of worldwide availability for state- of-the-art technology to ensure regulatory compliance.


Tese technologies automate processes, removing manual- intensive error-prone activities - key to meeting GMP requirements while at the same time managing costs.


Ken Appel is Manager Regulated Markets for Veriteq, Richmond, BC, Canada, www.vaisala.com/veriteq


www.scientistlive.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36